SUPN News and Press, Supernus Pharmaceuticals Inc. From 03/28/22

Supernus' Q4 earnings provide a first peek at a brand new Supernus. Qelbree is the big wildcard for Supernus investors; management has big dreams. Supernus' newly acquired and developing PD franchise will be important drivers of overall performance. For further details see: ...

Supernus Pharmaceuticals (NASDAQ:SUPN) notified the Nasdaq that it is not in compliance with the filing requirement due to its failure to timely file its annual report. SUPN currently anticipates filing its annual report on or before Apr. 4 and thereby regaining compliance with the filing rul...

ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, filed a notification of Late Filing on Form 12b-25 on ...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO o...

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2021 Earnings Conference Call February 28, 2022 04:30 PM ET Company Participants Peter Vozzo - Westwicke-Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Steinberg - Jefferie...

Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020 SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early October 2022 Completed acquisition of Adamas Pharmaceuticals, Inc. in November 2...

ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report prel...

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it received notice from the U.S. F...